Watchlist Price Alert

Olema Pharmaceuticals Inc... (OLMA)

NASDAQ: OLMA · Real-Time Price · USD

4.14

-0.05 (-1.19%)

At close: Jun 17, 2025, 10:46 AM

-1.19% (1D)

Bid	4.13
Market Cap	283.26M
Revenue (ttm)	n/a
Net Income (ttm)	-128.89M
EPS (ttm)	-2
PE Ratio (ttm)	-2.07
Forward PE	-1.91
Analyst	Buy

Ask	4.15
Volume	86,592
Avg. Volume (20D)	945,582
Open	4.28
Previous Close	4.19
Day's Range	4.10 - 4.29
52-Week Range	2.86 - 16.62
Beta	2.01

About OLMA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol OLMA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for OLMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

6 months ago

+0.89%

Olema Pharmaceutical shares are trading higher aft... Unlock content with Pro Subscription

News

3 weeks ago · zacks.com

Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?

The consensus price target hints at a 386.4% upside potential for Olema Pharmaceuticals (OLMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

1 month ago · zacks.com

Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 433.1% in Olema Pharmaceuticals (OLMA). While the effectiveness of this highly sought-after metric is questiona...

2 months ago · zacks.com

After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)

The heavy selling pressure might have exhausted for Olema Pharmaceuticals (OLMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre...

2 months ago · seekingalpha.com

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Olema Pharmaceuticals's palazestrant shows promise in late-stage trials for metastatic breast cancer, with potential FDA approval and commercial launch by 2027. Strong liquidity with $139.5 million in...